A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft
Suman Kambhampati1, Roger A Rajewski, Mehmet Tanol
1Cancer Research Unit, VA Medical Center, Kansas City, MO, USA. skambhampati@kumc.edu
Abstract:
2-Methoxyestradiol (2-ME2) is an endogenous metabolite of estradiol. In preclinical models, 2-ME2 is effective against different types of tumors. Unfortunately, only low systemic concentrations of 2-ME2 can be achieved following oral administration, even after very high doses are administered to patients. In an effort to solve this problem, we have now synthesized and tested a new prodrug of 2-ME2 that is water-soluble due to a bioreversible hydrophilic group added at the 3-position and that more effectively resists metabolic inactivation due to an ester moiety added to mask the 17-position alcohol. We are reporting here for the first time that this double prodrug of 2-ME2 is effective as an antiproliferative and anticancer agent for both in vitro and in vivo studies against Barrett esophageal adenocarcinoma (BEAC) and provided greater potency than 2-ME2 in inhibiting the growth of BEAC xenografts. Finally, studies indicate that, like 2-ME2, the 2-ME2-PD1 exhibits anticancer effect through possible disruption of microtubule network.
Insights
A novel 2-Methoxyestradiol (2-ME2) double prodrug demonstrates potent anticancer activity against Barrett esophageal adenocarcinoma (BEAC) in preclinical studies. This improved formulation overcomes low systemic concentration issues, offering greater efficacy than 2-ME2.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- 2-Methoxyestradiol (2-ME2), an endogenous estradiol metabolite, shows preclinical anticancer efficacy.
- Low systemic concentrations limit 2-ME2's therapeutic potential after oral administration.
- Barrett esophageal adenocarcinoma (BEAC) is a challenging cancer with limited treatment options.
Purpose of the Study:
- To develop and evaluate a novel, water-soluble double prodrug of 2-ME2 (2-ME2-PD1).
- To assess the antiproliferative and anticancer efficacy of 2-ME2-PD1 against BEAC in vitro and in vivo.
- To compare the potency of 2-ME2-PD1 with 2-ME2 in inhibiting BEAC xenograft growth.
Main Methods:
- Synthesis of a 2-ME2 double prodrug with a hydrophilic group at the 3-position and an ester moiety at the 17-position.
- In vitro antiproliferative assays against BEAC cell lines.
- In vivo studies using BEAC xenograft models in mice.
- Assessment of 2-ME2-PD1's mechanism of action, including microtubule network disruption.
Main Results:
- The synthesized 2-ME2 double prodrug (2-ME2-PD1) is water-soluble and resists metabolic inactivation.
- 2-ME2-PD1 exhibited significant antiproliferative and anticancer effects against BEAC in both in vitro and in vivo models.
- 2-ME2-PD1 demonstrated greater potency than 2-ME2 in inhibiting the growth of BEAC xenografts.
- Studies suggest 2-ME2-PD1, like 2-ME2, exerts its anticancer effect via disruption of the microtubule network.
Conclusions:
- The novel 2-ME2 double prodrug (2-ME2-PD1) is a promising anticancer agent for Barrett esophageal adenocarcinoma.
- This prodrug formulation effectively enhances the systemic availability and potency of 2-ME2.
- Further investigation into 2-ME2-PD1's therapeutic potential in esophageal cancer is warranted.
